CEL-SCI logo

CVM - CEL-SCI News Story

$12.78 -0.2  -1.2%

Last Trade - 4:28pm

Sector
Healthcare
Size
Mid Cap
Market Cap £356.2m
Enterprise Value £350.8m
Revenue £454k
Position in Universe 3120th / 6429

BRIEF-Cel-Sci’S Pivotal Phase 3 Study Has Reached The Required Number Of Events To Evaluate Data

Mon 4th May, 2020 1:34pm
May 4 (Reuters) - CEL-SCI Corp  CVM.A :
    * CEL-SCI’S PIVOTAL PHASE 3 STUDY HAS REACHED THE REQUIRED
NUMBER
OF EVENTS TO EVALUATE DATA FOR MULTIKINE IN TREATMENT OF HEAD
AND NECK CANCER

Source text for Eikon:  ID:nBwbqMGV7a 
Further company coverage:  CVM.A 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.